Hancock Jaffe Laboratories, Inc.

15 articles with Hancock Jaffe Laboratories, Inc.

• Hancock Jaffe Reports Successful Completion of First CoreoGraft Heart Bypass Surgery

  10/28/2020

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the first heart bypass surgery in HJLI's first-in-human CoreoGraft study was successfully completed and the patient has been discharged from the hospital.

• Hancock Jaffe Submits VenoValve Pre-IDE Filing to FDA

  10/27/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has submitted a Pre-IDE filing to the U.S. Food and Drug Administration and has requested a meeting with the FDA to discuss a few key matters in advance of the filing of its IDE application for the VenoValve U.S. pivotal trial.

• Hancock Jaffe Announces One Year Follow-up Data on Ninth VenoValve Patient

  10/21/2020

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the ninth VenoValve patient in HJLI's first-in-human, clinical study has successfully reached the one-year milestone.

• Hancock Jaffe to Begin CoreoGraft First-in-Human Study

  10/14/2020

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the first two surgeries for its CoreoGraft first-in-human study are scheduled to take place by the end of October.

• Hancock Jaffe Engages Syntactx for VenoValve U.S. Pivotal Trial

  10/8/2020

  Hancock Jaffe Laboratories, Inc. today announced that it has engaged Syntactx LLC to assist Hancock Jaffe with the VenoValve U.S. pivotal trial.

• Hancock Jaffe Laboratories, Inc. Announces Pricing of $5.1 Million Registered Direct Offering Priced at the Market

  10/7/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement.

• Hancock Jaffe Enrolls Initial Patients for First-in-Human CoreoGraft Study

  8/25/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has enrolled the first two patients for its first-in-human CoreoGraft study.

• Hancock Jaffe Regains Compliance with Nasdaq Stockholder's Equity Rule

  8/10/2020

  Hancock Jaffe Laboratories, Inc. today announced that HJLI has received formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has evidenced full compliance with the stockholders' equity requirement

• Hancock Jaffe Receives Permission to Proceed with First-in-Human CoreoGraft Study

  7/23/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Italian Hospital Asuncion in Paraguay has given the Company permission to proceed with the CoreoGraft first-in-human study. The study had been delayed due to constraints at the hospital caused by the COVID-19 pandemic.

• Hancock Jaffe Laboratories Announces Closings of $6.2 Million Offerings Including Full Exercise of Over-Allotment Option

  7/21/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the closings of an underwritten public offering, the full exercise of the underwriter's over-allotment option, and a private placement, for total gross proceeds of approximately $6.2 million, prior to deducting underwriting discounts, placement agent fees, and offering expenses.

• Hancock Jaffe Laboratories Announces Pricing of $5.6 Million Offering

  7/17/2020

  Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a $5.6 million offering, which consisted of an underwritten public offering of units and a private placement of units for gross proceeds of approximately $5.6 million, prior to deducting underwriting discounts and commissions and offering expenses payable by the company. The public offering is compris

• Hancock Jaffe Announces Registered Direct Offering Priced At Market

  6/2/2020

  Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $1.333 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement.

• Hancock Jaffe Announces Plans for CoreoGraft First-in-Human Study

  5/12/2020

  CoreoGraft Study Approved by the Superintendent of Health of the National Health Council of Paraguay

• 

  SoCal's Hancock Jaffe Laboratories Files for $20M IPO

  12/8/2017

  The firm is developing life-enhancing bioprosthetic devices and technologies for patients with debilitating cardiovascular diseases.

• Heart Valve Specialist Leman Cardiovascular SA Announces Full Acquisition Of Hancock Jaffe Laboratories, Inc.

  7/18/2006